銀川干細(xì)胞20170706

,會(huì)議內(nèi)容,青年論壇開(kāi)幕式、大會(huì)報(bào)告分會(huì)場(chǎng)（1/2/3）報(bào)告分會(huì)場(chǎng)（4/5/6）報(bào)告,CMV-specific T cell transfer promotes the quantitative and qualitive immune recovery for refractory CMV infection after haploidentical stem cell transplantation（Peking University Peoples Hospital）,Background: Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients，particularly in those patients who undergo haploidentical stem cell transplantation (haplo-SCT). Adoptive immunotherapies with CMV-specific T cells have been developed for the treatment of CMV infection，and several clinical trials have established the safety and efficacy of adoptive T cells for prophylaxis and treatment of CMV infection.However，few experiences have been reported about CMV-specific T cells in adoptive therapy post haplo-SCT.,Methods: A total of 32 patients with refractory CMV infection prospectively accepted adoptive CMV-specific T cells infusion following haplo-SCT were enrolled. Another group of 32 patients with non-refractory CMV infection after haplo-SCT was selected as controls. We analyzed the phenotypical and functional characteristics of CMV-specific T cells and their subsets before and after immunotherapy in the refractory CMV cohort， and also in the non-refractory CMV cohort. We aimed to(i) evaluate the safety and antiviral activity of CMV-specific T cells for refractory CMV infection in haplo-SCT recipients.,Results:Of the 32 treated patients，27 cleared CMV within 4 weeks posttransfer and were grouped into the early effective group. The remaining 5 patients who still experienced CMV recurrence after 4 weeks post adoptive transfer were grouped into the late effective group. In the early effective group，in vivo expansion of CMV-specific T cells，as well as improved cytokine production and proliferation ability of CMV-specific T cells were observed following cellular therapy. However，in remaining 5 patients who had CMV recurrence after 4 weeks post-transfer，neither the quantity nor the function of CMV-specific T cells were reversed.,Conclusions: Adoptive transfer of CMV-specific T cells would promote the quantitative and functional recovery of CMVspecific T cells that would guard against refractory CMV infection after haplo-SCT.,18 casesIn 83% of cases CMV infection was cleared or viral burden was significantly reduced Viral control was associated with in vivo expansion of CMV-specific T cells,異體干細(xì)胞治療牙周炎的基礎(chǔ)及轉(zhuǎn)化臨床研究王松靈首都醫(yī)科大學(xué),在大型動(dòng)物模型-小型豬上建立了牙周炎模型。用自體、異體牙源干細(xì)胞成功修復(fù)牙周炎致牙周骨缺損。牙源性干細(xì)胞再生牙周的效果比非牙源性干細(xì)胞好；牙髓干細(xì)胞保持細(xì)胞的干性及抗凋亡衰老能力明顯優(yōu)于其他干細(xì)胞。牙髓干細(xì)胞懸液注射組可以用于相對(duì)輕型的牙周病組織再生。18例異體牙髓干細(xì)胞治療慢性牙周炎臨床研究表明有明顯牙周組織再生，無(wú)副作用。通過(guò)建立牙源干細(xì)胞庫(kù)、牙髓干細(xì)胞注射液新藥應(yīng)用到臨床,人牙髓間充質(zhì)干細(xì)胞注射液,自體干細(xì)胞技術(shù)的臨床應(yīng)用肖海蓉石桂來(lái)博雅干細(xì)胞科技有限公司,博雅集團(tuán)旗下 Cesca 公司(納斯達(dá)克上市企業(yè))是全球領(lǐng)先的干細(xì)胞自動(dòng)化設(shè)備供應(yīng)商，擁有全球市場(chǎng)占有率超過(guò) 60%的臍帶血干細(xì)胞自動(dòng)化分離設(shè)備(AutoXpress)及全球唯一的自動(dòng)化液氮存儲(chǔ)裝置(BioArchive)。利用自主研發(fā)的手術(shù)室即時(shí)系統(tǒng)(ResQTM60、 MarrowXpressTM)，Cesca公司開(kāi)展了自體骨髓單核細(xì)胞治療重癥下肢缺血、急性心肌梗死、骨折不愈合等疾病的臨床研究。其中，重癥下肢缺血的 1/II 期臨床試驗(yàn)(n=17)已經(jīng)完成， 患者無(wú)治療相關(guān)副作用，1年無(wú)截肢生存率為 82.4%，旁側(cè)血管數(shù)量與尺寸等指標(biāo)顯著改善； FDA 已經(jīng)批準(zhǔn)開(kāi)展 III 期臨床試驗(yàn)。,臨床級(jí)臍帶間充質(zhì)細(xì)胞制備及鑒定方法研究袁艷鵬等首都醫(yī)科大學(xué)宣武醫(yī)院,目的：在 GLP 實(shí)驗(yàn)室中制備并鑒定臨床級(jí)臍帶間充質(zhì)細(xì)胞方法：新鮮獲取的臍帶去除血管并進(jìn)行充分清洗，獲得的華通膠(Whartons jelly)機(jī)械分離后分別進(jìn)行直接貼壁法和不同的酶消化法，比較獲取臍帶間充質(zhì)細(xì)胞的數(shù)量差別；用不同的無(wú)血清培養(yǎng)基進(jìn)行培養(yǎng)比較細(xì)胞形態(tài)是否良好， 得到最佳形態(tài)的臍帶間充質(zhì)細(xì)胞。體外培養(yǎng)第 3 代后進(jìn)行臍帶間充質(zhì)細(xì)胞質(zhì)檢，包括細(xì)胞活性，生長(zhǎng)曲線(xiàn)，無(wú)菌檢測(cè)，人類(lèi)相關(guān)病毒、支原體、內(nèi)毒素檢測(cè)，染色體核型分析， FACS 免疫表型檢測(cè)及分化能力檢測(cè)。 不同消化方法獲取細(xì)胞數(shù)之間比較采用兩樣本配對(duì) t 檢驗(yàn)。,結(jié)果:膠原酶消化獲得的臍帶間充質(zhì)細(xì)胞數(shù)(5.3106/ml)與膠原酶+0.25胰酶消化法(2.53105/ml)及直接貼壁法(2.6105/ml)之間存在顯著性差異(P0.0001)；MesenCult-ACF Medium （上海鈺博生物）培養(yǎng)獲得的 UC-MSC 形態(tài)最佳； UC-MSC 質(zhì)檢細(xì)胞活性?xún)龃媲斑_(dá)99.8， 凍存復(fù)蘇后達(dá) 99； 無(wú)細(xì)菌/支原體/乙肝病毒/丙肝病毒/梅毒螺旋體/艾滋病毒/肺炎支原體/EB 病毒/巨細(xì)胞病毒污染； 內(nèi)毒素檢測(cè)結(jié)果均1EU； CD73/CD90/CD105 陽(yáng)性率達(dá)98， CD